The layoffs first started last month, when Tesla began laying off what was said to be at the time 10 percent of the company’s ...
Swiss drugmaker Sandoz launched its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira biosimilar to hit the U.S. market, priced at a 5% and 55% ...
The move comes after the Elon Musk-led automaker disbanded its EV charging department following Tesla’s announcement last ...
Tesla disclosed last month that it expects to book more than $350 million in costs in the second quarter for the mass layoffs ...
Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...
The drug-pricing watchdogs over at the Institute for Clinical and Economic Review tend to be supportive of gene therapy ...
In this edition of Week in Review (WiR), we recap Google's recent layoffs -- and Tesla's -- and the UnitedHealthcare hacks.
Japanese biotech Ono Pharmaceutical is acquiring Deciphera Pharmaceuticals for $2.4 billion. Bristol Myers Squibb agreed to a ...
Electric-vehicle maker Tesla has laid off staff from the software, service and engineering departments, tech publication Electrek reported on Monday, citing sources familiar with the matter.
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.